FIELD: medicine.
SUBSTANCE: EGFL7 antibody is described. Offered is a pharmaceutical composition for vessel development modulation containing an effective amount of EGFL7 antibody. There are presented a polynucleotide coding said EGFL7 antibody, an expression vector containing said polynucleotide, a host cell able to express exogenous genetic material containing said vector. There is described a method of angiogenesis reduction or inhibition in a subject having a pathological condition associated with angiogenesis including the introduction to the subject of an effective amount of EGFL7 antibody or the pharmaceutical composition containing said antibody. There is offered a method for providing higher efficacy of an antiangiogenic agent in the subject having the pathological condition associated with angiogenesis including the introduction to the subject of EGFL7 antibody or the pharmaceutical composition containing said antibody.
EFFECT: invention extends the range of products available for vessel development modulation.
46 cl, 9 dwg, 2 tbl, 2 ex
